Virus-Specific T cells: Promising Adoptive T cell Therapy against Infectious Diseases following Hematopoietic Stem Cell Transplantation

Hematopoietic stem cell transplantation (HSCT) is a life-saving therapy for various hematologic disorders. Due to the bone marrow suppression and its long recovery period, secondary infections, like cytomegalovirus (CMV), Epstein-Bar virus (EBV), adenovirus (AdV), are leading causes of morbidity mortality in HSCT cases. Drug resistance antiviral pharmacotherapies makes researchers develop adoptive T therapies virus-specific therapy. These studies have faced major challenges such as finding most effective expansion methods, isolating expected subtype, defining functionality end-cell population, product quality control, clinical complications after injection. This review discusses viral infections HSCT, cells characteristics during chronic infection, application (VSTs) refractory standard methods producing VSTs their limitation, experiences on VSTs, focusing outcomes side effects that can be helpful decision-making patients further researches.